April saw quite a bit of movement in the biotech C-Suites, including both departures and arrivals. Read on for a whirlwind, worldwide tour of recent personnel moves.

4月，生物技术领域的高层人事变动频繁，既有离职也有新任命。接下来，让我们快速浏览一下近期全球范围内的人事变动。

Leadership shuffle at Novo Nordisk.

诺和诺德领导层洗牌。

The departure of

出发

Camilla Sylvest

西尔维斯特·卡米拉

, EVP commercial strategy and corporate affairs, from Novo Nordisk prompted some shuffling in the company’s executive management team. Rare disease EVP and president

，执行副总裁（EVP）商业战略与企业事务负责人，来自诺和诺德，促使公司高管团队进行了一些调整。罕见病EVP兼总裁

Ludovic Helfgott

吕多维克·赫尔夫戈特

, who joined the company in 2019 from AstraZeneca, will take over product and portfolio strategy, including commercial strategy, medical affairs, and business development, across the company. SVP product supply, emerging technologies,

，他于2019年从阿斯利康加入公司，将接管全公司的产品和组合策略，包括商业策略、医学事务和业务发展。高级副总裁，产品供应，新兴技术，

Thilde Hummel Bøgebjerg

希尔德·胡梅尔·伯格比jerne

, who has been at Novo for 18 years, will be promoted to executive vice president of quality, IT, and environmental affairs.

，已经在诺和工作了18年，将被提升为质量、IT和环境事务的执行副总裁。

Departures and appointments at Galapagos.

加拉帕戈斯的出发和任命。

Belgium-based cell therapy outfit Galapagos has seen significant changes in its leadership team.

总部位于比利时的细胞治疗公司Galapagos的领导团队发生了重大变化。

Dr Paul Stoffels

保罗·斯托弗斯博士

, who has been chair and CEO since 2022, announced his intention to retire as soon as a successor is found. Stoffels, who oversaw the acquisitions of CellPoint and Abound Bio during his tenure, will remain on the Board. Additionally,

自 2022 年担任主席兼首席执行官的斯托费尔斯宣布，一旦找到继任者，他打算退休。在任职期间监督了对 CellPoint 和 Abound Bio 收购的斯托费尔斯将继续留在董事会。此外，

Thad Huston

赛德·赫斯顿

, CFO and COO, has left the company for personal and professional reasons. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc, to support the company's transformation into a cell therapy-focused biotech.

，首席财务官兼首席运营官，因个人和职业原因已离开公司。赫斯顿于2023年从Kite Pharma公司加入Galapagos NV，以支持公司向专注于细胞治疗的生物技术企业转型。

Meanwhile at SpinCo, a new spinoff of Galapagos,

同时，在加拉帕戈斯的新分拆公司SpinCo，

Henry Gosebruch

亨利·戈塞布鲁赫

was appointed CEO. Gosebruch was previously president and CEO at Neumora, a clinical-stage biopharmaceutical company focused on neuroscience drug development. Before Neumora, he served as EVP and chief strategy officer at AbbVie.

被任命为首席执行官。戈塞布鲁赫此前曾担任临床阶段生物制药公司Neumora的总裁兼首席执行官，该公司专注于神经科学药物开发。在加入Neumora之前，他曾在艾伯维担任执行副总裁兼首席战略官。

T

T

wo biotechs welcome new CEOs.

我欢迎生物技术公司新任首席执行官。

Both Swedish immunology company Hansa Biopharma and California AI-powered oligonucleotide engineering biotech Creyon Bio announced new top leadership in April.

今年4月，瑞典免疫学公司Hansa Biopharma和加州人工智能驱动的寡核苷酸工程生物技术公司Creyon Bio都宣布了新的高层领导。

Renée Aguir-Lucander

雷内·阿吉尔-卢坎德

is in at Hansa—she previously served as CEO of Calliditas Therapeutics AB for seven years, where she successfully led the company through a dual listing on NASDAQ in both Sweden and the US. And Creyon Bio’s new CEO

在汉萨公司任职——她之前担任Calliditas Therapeutics AB的首席执行官长达七年，期间成功带领公司在瑞典和美国的纳斯达克双重上市。而Creyon Bio的新任首席执行官

Serge Messerlian

塞尔日·梅塞里安

is the former CEO of Teon Therapeutics and former president of Janssen Oncology, where he led the development and commercialisation of multiple cancer therapies.

是Teon Therapeutics的前首席执行官和Janssen Oncology的前总裁，他在任期间领导了多种癌症疗法的开发和商业化。

Biotechs announce medical and scientific leadership.

生物技术公司宣布医疗和科学领导地位。

Several biotechs added to the scientific side of the C-Suite.

几家生物技术公司加入了科学方面的C级管理层。

Dr Celine Wilke

威尔克·塞琳博士

joined ITM, a German radiopharmaceuticals company, as chief medical officer. Wilke has previously held various senior leadership positions at Novartis, overseeing clinical trials that led to the global approvals of Pluvicto and Locametz.

加入德国放射性药物公司ITM，担任首席医学官。威尔克此前曾在诺华担任过多个高级领导职务，监督了Pluvicto和Locametz的全球批准所需的临床试验。

Dr Leonardo Viana Nicacio

莱昂纳多·维亚纳·尼西亚西奥博士

was appointed chief medical officer of Protara Therapeutics, an NYC biotech focused on cancer and rare disease. Prior to this appointment, Nicacio held clinical development leadership roles at Stemline Therapeutics, Seagen (acquired by Pfizer in 2023), and AstraZeneca.

被任命为总部位于纽约市的生物技术公司Protara Therapeutics的首席医疗官，该公司专注于癌症和罕见病。在此次任命之前，Nicacio曾在Stemline Therapeutics、Seagen（2023年被辉瑞收购）和阿斯利康担任临床开发领导职务。

Haley Laken

海莉·莱肯

joined Massachusetts auto-immune therapy developer Zenas BioPharma as chief scientific officer. Laken was previously chief operating officer at Tabby Therapeutics and chief development officer at Jounce Therapeutics.

加入马萨诸塞州自体免疫疗法开发商Zenas BioPharma，担任首席科学官。Laken此前曾担任Tabby Therapeutics的首席运营官和Jounce Therapeutics的首席开发官。

Transgene and Telix add tech leaders.

Transgene 和 Telix 增加了技术领导者。

At Transgene, a Strasbourg, France-based biotech working on virus-based immunotherapies for cancer,

在法国斯特拉斯堡从事基于病毒的癌症免疫疗法的生物技术公司Transgene，

Simone Steiner

西蒙娜·施泰纳

was appointed chief technical officer. Steiner most recently served as chief technical operating officer at T-knife Therapeutics and has over 10 years of experience at Novartis.

被任命为首席技术官。施泰纳最近在T-knife Therapeutics担任首席技术运营官，并在诺华拥有超过10年的经验。

Also in April,

同样在四月，

Paul Schaffer

保罗·沙弗

joined Melbourne radiopharmaceutical shop Telix Pharmaceuticals as chief technology officer. Schaffer came in through Telix’s acquisition of ARTMS Inc, where he has led technology for the past seven years. He has also served as director of life sciences at TRIUMF, Canada’s particle accelerator research centre, since 2012..

加入墨尔本放射性药物公司Telix Pharmaceuticals，担任首席技术官。Schaffer是通过Telix收购ARTMS Inc加入的，在过去七年中，他一直领导该公司的技术发展。自2012年以来，他还曾担任加拿大粒子加速器研究中心TRIUMF的生命科学总监。

A bevy of new CFOs.

一大批新任首席财务官。

We saw several appointments last month to the top finance post.

我们看到上个月有几个被任命为最高财政职位。

Fang Z Ni

方梓倪

joined Copenhagen ADC developer Adcendo ApS from Black Diamond Therapeutics, where he served as chief business and financial officer.

加入哥本哈根ADC开发商Adcendo ApS之前，他在Black Diamond Therapeutics担任首席商务和财务官。

Astraveus, a Paris cell therapy company, tapped

一家巴黎的细胞疗法公司Astraveus，获得了

Laurence Riot Lamotte

劳伦斯·里奥特·拉莫特

for the role. Lamotte has led notable financings, including IntegraGen’s IPO.

对于这一角色，拉莫特曾主导过多次重要的融资活动，包括IntegraGen的首次公开募股（IPO）。

Soumya Chandramouli

苏米娅·钱德拉穆利

joined Belgian biotech Novadip as CFO, bringing 25 years of experience in financial management, most recently as CFO of IBA Group.

加入比利时生物技术公司Novadip担任首席财务官，拥有25年的财务管理经验，最近曾担任IBA集团的首席财务官。

Actimed Therapeutics, a UK specialty pharma, brought on

英国专业制药公司Actimed Therapeutics引进了

Shaun Claydon

肖恩·克莱顿

, a chartered accountant with significant industry experience, including serving as CFO of Creabilis.

，一位拥有丰富行业经验的特许会计师，曾担任Creabilis的首席财务官。

Nxera adds two to C-Suite.

Nxera 在 C-Suite 增加了两名成员。

April saw

四月看到

Kiyoshi Kaneko

金子清

in as chief commercial officer at Nxera Pharma and

作为Nxera Pharma的首席商务官入职，并且

Mariko Nakafuji

中藤真理子

appointed chief legal officer. Kaneko previously held the position of SVP commercial organisation and corporate strategy for AstraZeneca in Japan, while Nakafuji joined Nxera in 2021 as General Counsel and played a key role in the company’s transformational acquisition of the Japan and South Korean businesses of Idorsia Pharmaceuticals.

任命为首席法律官。此前，金子先生曾担任阿斯利康日本的商业组织和企业战略高级副总裁，而中藤先生于2021年加入Nxera担任总法律顾问，并在公司对Idorsia制药的日本和韩国业务进行转型收购中发挥了关键作用。

Nxera is a Japanese biopharma company with assets in neurology, GI and immunology, metabolic disorders, and rare diseases..

Nxera是一家日本生物制药公司，专注于神经病学、胃肠病学和免疫学、代谢紊乱以及罕见疾病领域。

Three VP and director-level hires.

三位副总裁和总监级别的招聘。

Last but not least, three notable hires outside the C-Suite:

最后但并非最不重要的，还有三位值得注意的非C级职位招聘：

Dr Bo Wang

王博博士

was appointed SVP and head of biomedical AI at Xaira Therapeutics, a San Francisco biotech leveraging artificial intelligence to rethink the traditional drug development process. Wang is a professor at the University of Toronto, chief AI scientist at Canada’s largest research hospital system, and a Canadian Institute for Advanced Research (CIFAR) AI Chair at the Vector Institute..

被任命为旧金山生物技术公司Xaira Therapeutics的高级副总裁兼生物医学人工智能主管，该公司利用人工智能重新思考传统的药物开发过程。王是多伦多大学的教授，加拿大最大研究医院系统的首席人工智能科学家，同时也是Vector研究所的加拿大先进研究院（CIFAR）人工智能主席。

Mark Fife

马克·菲夫

joined UK biologics maker Glen Cova Scientific as director of preclinical development. Fife arrives from Nextera, where he led the establishment and expansion of the company’s preclinical department.

加入英国生物制品公司Glen Cova Scientific，担任临床前开发总监。菲夫此前就职于Nextera，领导了该公司临床前部门的建立与扩展工作。

Romain Pettenaro

罗马内·佩特纳罗

joined French genetic medicines company Coave Therapeutics as VP of business development. Pettenaro comes from Alexion, AstraZeneca Rare Disease, where he led or co-led several major strategic transactions, including a $1 billion AAV gene therapy portfolio purchase and licensing agreement focused on rare cardiovascular and neurological diseases..

加入了法国基因药物公司Coave Therapeutics，担任业务发展副总裁。佩特纳罗此前就职于Alexion、阿斯利康罕见病部门，期间领导或共同领导了多项重大战略交易，包括一项价值10亿美元的AAV基因疗法组合购买和许可协议，专注于罕见的心血管和神经系统疾病。

That’s it for our pharma and biotech hires for April, but stay tuned for our other hires round-ups and remember, you can send your own hires to editorial@pharmaphorum.com for inclusion in this column.

以上就是我们四月份的制药和生物技术招聘情况，但请继续关注我们的其他招聘汇总，并记住，您可以将自己的招聘信息发送至editorial@pharmaphorum.com，以便在此专栏中发布。